Withholding JAK, IL-17 inhibitors fails to improve COVID-19 vaccine booster response
WASHINGTON — Withholding Janus kinase or interleukin-17 inhibitors from patients with rheumatoid arthritis or spondyloarthritis does not significantly benefit COVID-19 booster response, according to data presented at ACR Convergence 2024. “This trial, COVER, is a pragmatic platform trial conducted under a master protocol that randomized patients with rheumatoid arthritis or